• Entered 2026 with major U.S. regulatory momentum following FDA clearances
• Expanded clinical trial enrolment capacity and added new sites
• Continued commercial pipeline growth and interest in the U.S. and globally

Imricor entered Q1 CY26 with major U.S. regulatory momentum following FDA clearances of NorthStar and the Vision-MR Diagnostic Catheter in January 2026. The company continued advancing its broader U.S. regulatory pathway and progressing its paediatric strategy. Clinically, Imricor materially expanded enrolment capacity in the VISABL-AFL trial and added Na Homolce Hospital in Prague to the VISABL-VT trial. Commercially, the company continued progressing hospitals across its active pipeline, with growing interest in the U.S. following recent FDA clearances, particularly for NorthStar. Cash receipts were US$62k, up 140% from Q4 CY25, but still temporarily impacted by non-revenue generating clinical trial activities. Underlying operating cash outflows were US$5.9 million, with the reported outflow of US$7.8 million including one-off investments and costs. Imricor ended the quarter with US$32.9 million / A$48.0 million in total cash and short-term investments.

Imricor expects operating cash outflow to trend back toward approximately US$6.0 million in Q2 CY26.